iBio (NYSE:IBIO) and Pharmaxis (OTCMKTS:PXSLY) Financial Review

Pharmaxis (OTCMKTS:PXSLY) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Valuation & Earnings

This table compares Pharmaxis and iBio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharmaxis	$8.75 million	3.03	-$9.36 million	N/A	N/A
iBio	$375,000.00	147.47	-$24.91 million	N/A	N/A

Pharmaxis has higher revenue and earnings than iBio.

Insider and Institutional Ownership

7.9% of iBio shares are held by institutional investors. 0.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Pharmaxis and iBio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharmaxis	0	0	0	0	0.00
iBio	0	0	2	0	3.00

iBio has a consensus target price of $4.30, suggesting a potential downside of 23.21%. Given iBio’s stronger consensus rating and higher probable upside, analysts plainly believe iBio is more favorable than Pharmaxis.

Risk & Volatility

Pharmaxis has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, iBio has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Profitability

This table compares Pharmaxis and iBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharmaxis	N/A	N/A	N/A
iBio	N/A	-73.15%	-45.51%

Summary

iBio beats Pharmaxis on 7 of the 11 factors compared between the two stocks.

About Pharmaxis

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

About iBio

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.